Review Article
Multimodal Liver-Directed Management of Neuroendocrine Hepatic Metastases
Table 6
Summary of outcomes for liver transplantation for neuroendocrine metastases. OS: overall survival.
| | Author, publication year | No. of liver transplant (LT) patients | Survival data | Predictors of survival |
| | Gedaly, 2011 [76] | 150 [13 receiving another organ at time of LT] | 49% 5-year survival [excluding multiple organ transplants] | Regardless of age, improved survival (>60% at 5 years) for patients waiting more than 2 months for transplant () | | Mathe, 2011 [77] | 89 | 44% 5-year survival | Worse survival with recipient age >55 () and simultaneous LT-pancreas resection () | | Rosenau, 2002 [78] | 19 | 80% 5-year survival
50% 10-year survival | Ki-67 <5% and normal E-cadherin expression had 100% 7-year survival (versus 0% when Ki-67% >5% or aberrant E-cadherin expression, ) | | Le Treut, 2008 [79] | 85 [34 with concurrent extrahepatic resection] | Median OS: 56 months | Exenteration (), a duodenopancreatic primary (), and hepatomegaly (), all predicted for poorer survival |
|
|
